Israilova Malika, Tanaka Takashi, Suzuki Fumiko, Morishima Shigeru, Muramatsu Ikunobu
Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, School of Medicine, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
J Pharmacol Exp Ther. 2004 Apr;309(1):259-66. doi: 10.1124/jpet.103.061796. Epub 2004 Jan 13.
We established three human embryonic kidney (HEK) 293 cell lines stably expressing alpha(1)-adrenoceptor (AR) subtypes, one (alpha(1A), (1B)-AR) coexpressing both receptors and the other two (alpha(1A)-AR and alpha(1B)-AR) expressing each receptor in isolation. In the alpha(1A), (1B)-AR cells, both receptors were clearly distinguished by the alpha(1A)-selective ligands (-)-1(3-hydroxypropyl)-5-((2R)-2-([2-(2,2,2-trifluoroethyl]oxy]phenyl)oxy)ethyl]amino)propyl)-2,3-dihydro-1H-indole-7-carboxamide (KMD-3213) and methoxamine, but not by the subtype-nonselective ligands prazosin and phenylephrine. In all three cell lines, phenylephrine caused a concentration-dependent increase in inositol phosphates and an increase in extracellular signal-regulated kinase 1/2 (ERK1/2) activation. However, there was a 2-fold or greater maximal response to phenylephrine and a somewhat higher agonist potency in ERK1/2 activation in the alpha(1A,1B)-AR cells, compared with the responses of cells expressing either receptor individually (alpha(1A)-AR or alpha(1B)-AR). Furthermore, the antagonistic affinities of prazosin (pK(b) of 10.1) and KMD-3213 (9.4) for inhibiting the phenylephrine response were intermediate between the values for inhibition in alpha(1A)-AR cells (prazosin, 9.3; KMD-3213, 10.5) and alpha(1B)-AR cells (prazosin, 11.0; KMD-3213, 8.1). The inhibitor pK(b) values in alpha(1A), (1B)-AR also differed from their ligand binding affinities measured in alpha(1A)-AR and alpha(1B)-AR cells. In contrast, the alpha(1A)-selective agonist methoxamine, which did not activate alpha(1B)-AR cells, stimulated either alpha(1A,) (1B)-AR or alpha(1A)-AR cells with a comparable potency and maximum effectiveness. Our data indicate that when coexpressed in the same cell, the activation of common pathways by individual AR receptor subtypes by a nonselective agonist can exhibit enhanced responsiveness and a distinct antagonist affinity compared with the parameters for the same receptors, when expressed alone in the same cell background.
我们建立了三种稳定表达α(1)-肾上腺素能受体(AR)亚型的人胚肾(HEK)293细胞系,一种(α(1A),(1B)-AR)共表达两种受体,另外两种(α(1A)-AR和α(1B)-AR)分别单独表达每种受体。在α(1A),(1B)-AR细胞中,两种受体可通过α(1A)选择性配体(-)-1(3-羟丙基)-5-((2R)-2-([2-(2,2,2-三氟乙基]氧基]苯基)氧基)乙基]氨基)丙基)-2,3-二氢-1H-吲哚-7-甲酰胺(KMD-3213)和甲氧明清晰区分,但不能通过亚型非选择性配体哌唑嗪和去氧肾上腺素区分。在所有三种细胞系中,去氧肾上腺素引起肌醇磷酸浓度依赖性增加以及细胞外信号调节激酶1/2(ERK1/2)激活增加。然而,与单独表达任一受体的细胞(α(1A)-AR或α(1B)-AR)的反应相比,α(1A,1B)-AR细胞中去氧肾上腺素的最大反应高2倍或更大,且在ERK1/2激活中的激动剂效力略高。此外,哌唑嗪(pK(b)为10.1)和KMD-3213(9.4)抑制去氧肾上腺素反应的拮抗亲和力介于α(1A)-AR细胞(哌唑嗪,9.3;KMD-3213,10.5)和α(1B)-AR细胞(哌唑嗪,11.0;KMD-3213,8.1)中的抑制值之间。α(1A),(1B)-AR中的抑制剂pK(b)值也与其在α(1A)-AR和α(1B)-AR细胞中测量的配体结合亲和力不同。相比之下,不激活α(1B)-AR细胞的α(1A)选择性激动剂甲氧明,以相当的效力和最大效能刺激α(1A),(1B)-AR或α(1A)-AR细胞。我们的数据表明,当在同一细胞中共表达时,与在相同细胞背景中单独表达时相比,非选择性激动剂通过单个AR受体亚型激活共同途径可表现出增强的反应性和独特的拮抗亲和力。